We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson & Johnson announced Tuesday that fourth-quarter sales of prescription drugs rose 2.1 percent year-over-year to $8.2 billion, with growth driven by revenue from new products including Imbruvica, Darzalex and Xarelto.